Gerlach, Lorena
Beyer, Anna-Sophia Liselott
Kaemmerer, Daniel
Sänger, Jörg
Evert, Katja
Schulz, Stefan
Lupp, Amelie
Funding for this research was provided by:
Universitätsklinikum Jena
Article History
Received: 6 February 2023
Accepted: 31 October 2023
First Online: 3 November 2023
Competing interests
: Daniel Kaemmerer received support for travelling to meetings by the companies IPSEN and PFIZER. Stefan Schulz is the founder and scientific advisor of 7TM Antibodies GmbH, Jena, Germany, and declares no competing non-financial interests but competing financial interests. All other authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.